MX2020002500A - Adn de extremo cerrado modificado (adnec). - Google Patents
Adn de extremo cerrado modificado (adnec).Info
- Publication number
- MX2020002500A MX2020002500A MX2020002500A MX2020002500A MX2020002500A MX 2020002500 A MX2020002500 A MX 2020002500A MX 2020002500 A MX2020002500 A MX 2020002500A MX 2020002500 A MX2020002500 A MX 2020002500A MX 2020002500 A MX2020002500 A MX 2020002500A
- Authority
- MX
- Mexico
- Prior art keywords
- cedna
- cedna vectors
- linear
- vectors
- ended dna
- Prior art date
Links
- 239000013598 vector Substances 0.000 abstract 4
- 230000014509 gene expression Effects 0.000 abstract 3
- 108700019146 Transgenes Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/60—Vectors comprising a special translation-regulating system from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556319P | 2017-09-08 | 2017-09-08 | |
| US201762556324P | 2017-09-08 | 2017-09-08 | |
| US201762556335P | 2017-09-08 | 2017-09-08 | |
| US201762556281P | 2017-09-08 | 2017-09-08 | |
| US201762556331P | 2017-09-08 | 2017-09-08 | |
| US201762556329P | 2017-09-08 | 2017-09-08 | |
| PCT/US2018/049996 WO2019051255A1 (en) | 2017-09-08 | 2018-09-07 | CLOSED-ENDED DNA (CEDNA) MODIFIED |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002500A true MX2020002500A (es) | 2020-09-17 |
Family
ID=65635235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002500A MX2020002500A (es) | 2017-09-08 | 2018-09-07 | Adn de extremo cerrado modificado (adnec). |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200283794A1 (https=) |
| EP (1) | EP3678710A4 (https=) |
| JP (3) | JP2020532981A (https=) |
| KR (1) | KR20200051011A (https=) |
| CN (1) | CN111132699A (https=) |
| AU (1) | AU2018327348A1 (https=) |
| BR (1) | BR112020004151A2 (https=) |
| CA (1) | CA3075168A1 (https=) |
| IL (1) | IL272797A (https=) |
| MA (1) | MA50100A (https=) |
| MX (1) | MX2020002500A (https=) |
| PH (1) | PH12020500465A1 (https=) |
| SG (1) | SG11202000698SA (https=) |
| UA (1) | UA129010C2 (https=) |
| WO (1) | WO2019051255A1 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| TW202545984A (zh) | 2017-08-09 | 2025-12-01 | 美商生物化學醫療公司 | 核酸分子及其用途 |
| KR20200093635A (ko) * | 2017-12-06 | 2020-08-05 | 제너레이션 바이오 컴퍼니 | 변형된 폐쇄된 말단 dna (cedna)를 사용한 유전자 편집 |
| WO2019118921A1 (en) | 2017-12-14 | 2019-06-20 | Flodesign Sonics, Inc. | Acoustic transducer drive and controller |
| MA51842A (fr) * | 2018-02-14 | 2020-12-23 | Generation Bio Co | Vecteurs d'adn non viraux et utilisations associées pour la production d'anticorps et de protéines de fusion |
| WO2020033863A1 (en) | 2018-08-09 | 2020-02-13 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| CN113316640A (zh) * | 2018-11-09 | 2021-08-27 | 世代生物公司 | 包含对称的被修饰的反向末端重复序列的被修饰的封闭端dna(cedna) |
| GB201905651D0 (en) * | 2019-04-24 | 2019-06-05 | Lightbio Ltd | Nucleic acid constructs and methods for their manufacture |
| EP3999646A4 (en) * | 2019-07-17 | 2023-08-30 | Generation Bio Co. | COMPOSITIONS AND PRODUCTION OF NICKEL-CLOSED CLOSED-END DNA VECTOR |
| AU2020315444A1 (en) * | 2019-07-17 | 2021-12-23 | Generation Bio Co. | Synthetic production of single-stranded adeno associated viral DNA vectors |
| BR112022002794A2 (pt) * | 2019-08-15 | 2022-08-09 | Childrens Hospital Philadelphia | Terapia combinada de transgene e mirna derivado de íntron para tratamento de sca1 |
| JP7700101B2 (ja) * | 2019-09-06 | 2025-06-30 | ジェネレーション バイオ カンパニー | 閉端ｄｎａおよび切断可能脂質を含む脂質ナノ粒子組成物ならびにそれらの使用方法 |
| GB2700048B (en) | 2019-09-18 | 2026-03-04 | Aldevron Llc | synthetic dna vectors and method of use |
| WO2021072031A1 (en) * | 2019-10-11 | 2021-04-15 | Insideoutbio, Inc. | Methods and compositions for the manufacture and use of circular dna encoded therapeutics for genetic disorders and other diseases |
| WO2021169167A1 (en) * | 2020-02-29 | 2021-09-02 | Nanjing GenScript Biotech Co., Ltd. | Method for treating coronavirus infections |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| MX2022011805A (es) * | 2020-03-24 | 2023-01-11 | Generation Bio Co | Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con factor ix. |
| AU2021244559A1 (en) * | 2020-03-24 | 2022-11-17 | Generation Bio Co. | Non-viral DNA vectors and uses thereof for expressing Gaucher therapeutics |
| US20230181764A1 (en) * | 2020-05-18 | 2023-06-15 | Generation Bio Co. | Novel lipids and nanoparticle compositions thereof |
| CN116234917A (zh) | 2020-07-27 | 2023-06-06 | 安杰瑞姆生物科学公司 | Dna分子组合物及其制备方法和使用方法 |
| US20220243201A1 (en) * | 2020-08-23 | 2022-08-04 | Bioverativ Therapeutics Inc. | Engineered itr sequences and methods of use |
| US20220090130A1 (en) | 2020-08-23 | 2022-03-24 | Bioverativ Therapeutics Inc. | MODIFIED BACULOVIRUS SYSTEM FOR IMPROVED PRODUCTION OF CLOSED-ENDED DNA (ceDNA) |
| AU2021342503A1 (en) * | 2020-09-16 | 2023-04-06 | Generation Bio Co. | Non-viral DNA vectors and uses thereof for expressing FVIII therapeutics |
| US20240026374A1 (en) * | 2020-09-16 | 2024-01-25 | Generation Bio Co. | Closed-ended dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) |
| GB202014751D0 (en) * | 2020-09-18 | 2020-11-04 | Lightbio Ltd | Targeting vector |
| CA3211687A1 (en) * | 2021-03-19 | 2022-09-22 | Ozan ALKAN | Non-viral dna vectors and uses thereof for expressing pfic therapeutics |
| WO2022232029A2 (en) * | 2021-04-26 | 2022-11-03 | University Of Florida Research Foundation, Incorporated | Synthetic aav vectors for repeated delivery of therapeutic genes |
| EP4329884A1 (en) * | 2021-04-27 | 2024-03-06 | Generation Bio Co. | Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof |
| CN117881786A (zh) * | 2021-04-27 | 2024-04-12 | 世代生物公司 | 表达治疗性抗体的非病毒dna载体及其用途 |
| CN117729934A (zh) * | 2021-05-07 | 2024-03-19 | 世代生物公司 | 用于疫苗递送的非病毒dna载体 |
| WO2022236016A1 (en) * | 2021-05-07 | 2022-11-10 | Generation Bio Co. | Lyophilized non-viral dna vector compositions and uses thereof |
| US20250027107A1 (en) * | 2021-10-18 | 2025-01-23 | Flagship Pioneering Innovations Vii, Llc | Dna compositions and related methods |
| WO2023177655A1 (en) | 2022-03-14 | 2023-09-21 | Generation Bio Co. | Heterologous prime boost vaccine compositions and methods of use |
| CN117802161A (zh) * | 2022-06-30 | 2024-04-02 | 苏州吉恒基因科技有限公司 | 精准重组腺相关病毒载体及其用途 |
| WO2024040222A1 (en) * | 2022-08-19 | 2024-02-22 | Generation Bio Co. | Cleavable closed-ended dna (cedna) and methods of use thereof |
| AU2024229184A1 (en) | 2023-03-02 | 2025-08-28 | Krystal Biotech, Inc. | Interleukin-2 and interleukin-12 for cancer therapy |
| US11891617B1 (en) * | 2023-03-27 | 2024-02-06 | Genecraft Inc. | Modified complex platform of adeno-associated virus with improved rate of expression of loaded genes and reduced genotoxicity |
| US11993783B1 (en) * | 2023-03-27 | 2024-05-28 | Genecraft Inc. | Nucleic acid molecule comprising asymmetrically modified ITR for improving expression rate of inserted gene, and use thereof |
| US11767541B1 (en) * | 2023-03-27 | 2023-09-26 | Genecraft, Inc. | Adeno-associated virus complex with improved expression of RUNX3 gene and uses for preventing or treating KRAS mutated lung cancer |
| EP4698646A2 (en) * | 2023-04-21 | 2026-02-25 | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 1475 North Scottsdale Road | Novel transmembrane sensors and method of characterization for lysis-free detection of intracellular targets |
| WO2025114932A1 (en) * | 2023-11-30 | 2025-06-05 | Sanofi | Purification of closed-ended dna molecules |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050019824A1 (en) * | 1994-03-08 | 2005-01-27 | Human Genome Sciences, Inc. | Fibroblast Growth Factor-10 |
| US20050026838A1 (en) * | 1995-06-05 | 2005-02-03 | Human Genome Sciences, Inc. | Fibroblast Growth Factor-13 |
| DE10044384A1 (de) * | 2000-09-08 | 2002-04-18 | Medigene Ag | Wirtszellen zur Verpackung von rekombinantem Adeno-assoziiertem Virus (rAAV), Verfahren zu ihrer Herstellung und deren Verwendung |
| WO2005072364A2 (en) * | 2004-01-27 | 2005-08-11 | University Of Florida | A modified baculovirus expression system for production of pseudotyped raav vector |
| WO2008016391A2 (en) * | 2006-01-31 | 2008-02-07 | The Board Of Trustees Of The Leland Stanford Junior University | Self-complementary parvoviral vectors, and methods for making and using the same |
| EP2500434A1 (en) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| AU2013281328B2 (en) * | 2012-06-27 | 2017-11-23 | MeiraGTx Gene Regulation Limited | Combination for treating an inflammatory disorder |
| CN104087613B (zh) * | 2014-06-30 | 2017-08-29 | 中国科学院苏州生物医学工程技术研究所 | 基于aav‑itr的基因表达微载体及其构建方法和应用 |
| DK3402483T3 (da) * | 2016-01-15 | 2024-01-02 | American Gene Tech Int Inc | Fremgangsmåder og sammensætninger til aktivering af gamma-delta-T-celler |
| WO2017152149A1 (en) * | 2016-03-03 | 2017-09-08 | University Of Massachusetts | Closed-ended linear duplex dna for non-viral gene transfer |
-
2018
- 2018-09-07 JP JP2020512843A patent/JP2020532981A/ja active Pending
- 2018-09-07 CA CA3075168A patent/CA3075168A1/en active Pending
- 2018-09-07 UA UAA202000594A patent/UA129010C2/uk unknown
- 2018-09-07 KR KR1020207009737A patent/KR20200051011A/ko not_active Ceased
- 2018-09-07 AU AU2018327348A patent/AU2018327348A1/en not_active Abandoned
- 2018-09-07 BR BR112020004151-3A patent/BR112020004151A2/pt not_active Application Discontinuation
- 2018-09-07 SG SG11202000698SA patent/SG11202000698SA/en unknown
- 2018-09-07 EP EP18854941.4A patent/EP3678710A4/en active Pending
- 2018-09-07 MA MA050100A patent/MA50100A/fr unknown
- 2018-09-07 WO PCT/US2018/049996 patent/WO2019051255A1/en not_active Ceased
- 2018-09-07 US US16/644,568 patent/US20200283794A1/en not_active Abandoned
- 2018-09-07 CN CN201880058155.7A patent/CN111132699A/zh active Pending
- 2018-09-07 MX MX2020002500A patent/MX2020002500A/es unknown
-
2020
- 2020-02-20 IL IL272797A patent/IL272797A/en unknown
- 2020-03-06 PH PH12020500465A patent/PH12020500465A1/en unknown
-
2022
- 2022-11-02 JP JP2022176371A patent/JP2022190081A/ja active Pending
-
2024
- 2024-10-28 JP JP2024189111A patent/JP2025010253A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020532981A (ja) | 2020-11-19 |
| EP3678710A1 (en) | 2020-07-15 |
| EP3678710A4 (en) | 2021-06-09 |
| PH12020500465A1 (en) | 2021-01-25 |
| NZ761178A (en) | 2024-05-31 |
| CN111132699A (zh) | 2020-05-08 |
| UA129010C2 (uk) | 2024-12-25 |
| CA3075168A1 (en) | 2019-03-14 |
| RU2020109904A (ru) | 2021-10-08 |
| IL272797A (en) | 2020-04-30 |
| MA50100A (fr) | 2020-07-15 |
| AU2018327348A1 (en) | 2020-02-20 |
| BR112020004151A2 (pt) | 2020-09-08 |
| US20200283794A1 (en) | 2020-09-10 |
| KR20200051011A (ko) | 2020-05-12 |
| WO2019051255A1 (en) | 2019-03-14 |
| JP2022190081A (ja) | 2022-12-22 |
| JP2025010253A (ja) | 2025-01-20 |
| SG11202000698SA (en) | 2020-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500465A1 (en) | Modified closed-ended dna (cedna) | |
| PH12020550771A1 (en) | Gene editing using a modified closed-ended dna (cedna) | |
| MX2021004842A (es) | Adn de extremo cerrado (ceadn) modificado que comprende repeticiones terminales invertidas modificadas simetricas. | |
| SA518391294B1 (ar) | التحرير المتعدد للجينوم | |
| NZ742040A (en) | Engineered nucleic-acid targeting nucleic acids | |
| PH12021550904A1 (en) | Novel crispr/cas12f enzyme and system | |
| WO2015168547A3 (en) | In vivo gene engineering with adenoviral vectors | |
| MX2025014318A (es) | Vector de adenovirus de chimpance util para la administracion de neoantigenos | |
| EP3795581A3 (en) | New avv capsid proteins for nucleic acid transfer | |
| WO2016183438A8 (en) | Self-targeting genome editing system | |
| PH12018550020A1 (en) | Production of human milk oligosaccharides in microbial hosts with engineered import/export | |
| GB2569733A (en) | RNA-guided nucleic acid modifying enzymes and methods of use thereof | |
| MX2021003188A (es) | Composiciones y métodos para la manufactura de vectores de terapia génica. | |
| NZ738689A (en) | Engineered crispr-cas9 compositions and methods of use | |
| MX2015006220A (es) | Insercion de adn de tranferencia mediada por efectores tipo activadores de la transcripción (tal). | |
| AR113458A1 (es) | Método para regular la expresión génica | |
| GB2569734A (en) | RNA-guided nucleic acid modifying enzymes and methods of use thereof | |
| MX2020005458A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
| NZ712727A (en) | Compositions and methods of nucleic acid-targeting nucleic acids | |
| IN2014DN05963A (https=) | ||
| SG10201809075XA (en) | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues | |
| MX2016005488A (es) | Vector hsv oncolitico. | |
| WO2013049121A3 (en) | Recombinant phage and methods | |
| MX2018010172A (es) | Sistema vector inmunoestimulante novedoso. | |
| EP3760713A3 (en) | Lipase variants and polynucleotides encoding same |